Noile-Immune Biotech Inc. (JP:4893)

:4893

4893

Noile-Immune Biotech Inc.

RESEARCH TOOLSreports

Noile-Immune Biotech Inc. (4893) Price & Analysis

0 Followers

4893 Stock Chart & Stats

¥134.00

¥9.00(4.81%)

At close: Jan 08 4:00 PM EST

¥134.00

¥9.00(4.81%)

Day’s Range― - ―

52-Week Range¥120.00 - ¥217.00

Previous CloseN/A

Volume1.93M

Average Volume (3M)85.17K

Market Cap

¥6.40B

Enterprise Value¥2.49B

Total Cash (Recent Filing)¥4.31B

Total Debt (Recent Filing)¥0.00

Price to Earnings (P/E)―

Beta1.47

Next Earnings

May 19, 2026

EPS Estimate

-5.05

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-4.36

Shares Outstanding43,276,764

10 Day Avg. Volume110,290

30 Day Avg. Volume85,173

Financial Highlights & Ratios

PEG Ratio0.41

Price to Book (P/B)1.46

Price to Sales (P/S)1151.82

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-34

Revenue Forecast (FY)¥300.00M

Bulls Say, Bears Say

Bulls Say

Debt-free Balance SheetNo reported debt meaningfully reduces solvency and interest-rate risk, giving the company financial flexibility to fund R&D and clinical programs longer without fixed interest obligations. This structural strength improves negotiating leverage with partners and underwriters over the next several quarters.

Very High Gross MarginsNear-100% gross margins indicate that when products or services scale, incremental costs are low, enabling strong unit economics. For a therapeutics developer this suggests pricing power and attractive long-term profitability potential once revenue grows, supporting sustainable margin expansion post-commercialization.

Improving Cash Burn TrendA year-over-year reduction in cash burn signals better operational control or sequencing of spending, extending runway and reducing near-term financing pressure. If this trend persists, it lessens dilution risk and gives management time to advance programs toward value-inflecting milestones.

Bears Say

Collapsing RevenueSharp, persistent revenue declines undermine operating leverage and make fixed-cost coverage unpredictable. For a small biotech this raises concerns about commercialization timing, partner uptake, or one-off revenue loss; continued revenue weakness materially increases financing and execution risk over coming quarters.

Consistent Negative Operating Cash FlowRepeated negative operating cash flow forces reliance on external funding to maintain R&D and trials. That dependence creates persistent dilution or financing execution risk, limits strategic optionality, and can constrain the firm’s ability to reach clinical or commercial inflection points without raising capital.

Large Net Losses; Negative ROESustained large losses and negative ROE indicate shareholder capital is being eroded rather than compounded. Over the medium term this weakens the equity base, pressures future funding terms, and signals that current programs have yet to translate into profitable operations or returns for investors.

4893 FAQ

What was Noile-Immune Biotech Inc.’s price range in the past 12 months?

Noile-Immune Biotech Inc. lowest stock price was ¥120.00 and its highest was ¥217.00 in the past 12 months.

What is Noile-Immune Biotech Inc.’s market cap?

Noile-Immune Biotech Inc.’s market cap is ¥6.40B.

When is Noile-Immune Biotech Inc.’s upcoming earnings report date?

Noile-Immune Biotech Inc.’s upcoming earnings report date is May 19, 2026 which is in 44 days.

How were Noile-Immune Biotech Inc.’s earnings last quarter?

Noile-Immune Biotech Inc. released its earnings results on Feb 13, 2026. The company reported -¥4.36 earnings per share for the quarter, missing the consensus estimate of N/A by -¥4.36.

Is Noile-Immune Biotech Inc. overvalued?

According to Wall Street analysts Noile-Immune Biotech Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Noile-Immune Biotech Inc. pay dividends?

Noile-Immune Biotech Inc. does not currently pay dividends.

What is Noile-Immune Biotech Inc.’s EPS estimate?

Noile-Immune Biotech Inc.’s EPS estimate is -5.05.

How many shares outstanding does Noile-Immune Biotech Inc. have?

Noile-Immune Biotech Inc. has 43,276,764 shares outstanding.

What happened to Noile-Immune Biotech Inc.’s price movement after its last earnings report?

Noile-Immune Biotech Inc. reported an EPS of -¥4.36 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.938%.

Which hedge fund is a major shareholder of Noile-Immune Biotech Inc.?

Currently, no hedge funds are holding shares in JP:4893

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Noile-Immune Biotech Inc.

Noile-Immune Biotech Inc. researches and develops CAR-T cells for cancer immunotherapies. The company was incorporated in 2015 and is headquartered in Minato, Japan.